Pura Vida Investments LLC grew its stake in Verrica Pharmaceuticals Inc (NASDAQ:VRCA) by 219.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 63,916 shares of the company’s stock after buying an additional 43,916 shares during the quarter. Pura Vida Investments LLC owned approximately 0.25% of Verrica Pharmaceuticals worth $521,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of VRCA. Vanguard Group Inc increased its position in Verrica Pharmaceuticals by 950.7% in the third quarter. Vanguard Group Inc now owns 292,489 shares of the company’s stock worth $4,753,000 after buying an additional 264,651 shares in the last quarter. Vanguard Group Inc. increased its position in Verrica Pharmaceuticals by 950.7% in the third quarter. Vanguard Group Inc. now owns 292,489 shares of the company’s stock worth $4,753,000 after buying an additional 264,651 shares in the last quarter. BlackRock Inc. purchased a new stake in Verrica Pharmaceuticals in the third quarter worth about $4,145,000. Kornitzer Capital Management Inc. KS increased its position in Verrica Pharmaceuticals by 52.2% in the fourth quarter. Kornitzer Capital Management Inc. KS now owns 327,420 shares of the company’s stock worth $2,668,000 after buying an additional 112,275 shares in the last quarter. Finally, Point72 Asset Management L.P. purchased a new stake in Verrica Pharmaceuticals in the third quarter worth about $1,463,000. Institutional investors and hedge funds own 32.87% of the company’s stock.

Shares of VRCA opened at $12.90 on Friday. The stock has a market capitalization of $308.49 million and a price-to-earnings ratio of -9.15. Verrica Pharmaceuticals Inc has a 52 week low of $6.44 and a 52 week high of $23.29.

Verrica Pharmaceuticals (NASDAQ:VRCA) last released its earnings results on Thursday, March 7th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.03). As a group, sell-side analysts expect that Verrica Pharmaceuticals Inc will post -1.13 EPS for the current year.

In related news, major shareholder Matt Davidson sold 25,045 shares of the stock in a transaction dated Wednesday, March 13th. The stock was sold at an average price of $11.55, for a total transaction of $289,269.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, COO Linda Palczuk bought 3,000 shares of the business’s stock in a transaction that occurred on Wednesday, January 16th. The shares were acquired at an average price of $10.53 per share, with a total value of $31,590.00. The disclosure for this purchase can be found here. Insiders have sold 262,694 shares of company stock valued at $2,936,370 in the last quarter.

A number of analysts have commented on VRCA shares. HC Wainwright started coverage on Verrica Pharmaceuticals in a research report on Thursday, February 21st. They issued a “buy” rating and a $20.00 price target for the company. Zacks Investment Research upgraded Verrica Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, December 19th. One analyst has rated the stock with a sell rating and four have given a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $26.25.

TRADEMARK VIOLATION NOTICE: “Pura Vida Investments LLC Has $521,000 Holdings in Verrica Pharmaceuticals Inc (VRCA)” was first reported by Watch List News and is the property of of Watch List News. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The legal version of this report can be accessed at https://www.watchlistnews.com/pura-vida-investments-llc-has-521000-holdings-in-verrica-pharmaceuticals-inc-vrca/2897223.html.

Verrica Pharmaceuticals Profile

Verrica Pharmaceuticals Inc develops and commercializes dermatological treatments in the United States. The company is advancing its lead product VP-102, a proprietary topical therapy, in various common skin indications, including Molluscum contagiosum and Verruca Vulgaris. It is also developing 2 Phase 3 trials in molluscum contagiosum under NCT03377803 and NCT03377790.

Further Reading: Buy-Side Analysts

Want to see what other hedge funds are holding VRCA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Verrica Pharmaceuticals Inc (NASDAQ:VRCA).

Institutional Ownership by Quarter for Verrica Pharmaceuticals (NASDAQ:VRCA)

Receive News & Ratings for Verrica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verrica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.